- Auteur(s) : Maud Bezier, Ziad Reguiai, Fabien Vitry, Franck Broly, Philippe Bernard
, Department of Dermatology, Hôpital Robert-Debré, Centre Hospitalier de Reims, avenue du Général Koenig, 51092 Reims Cedex, France, UAM, Hôpital Maison Blanche, Centre Hospitalier de Reims, France, Laboratory of Biochemistry and Molecular Biology, Hôpital Calmette, Centre Hospitalier de Lille, France
- Mots-clés : autoimmune bullous disease, thiopurine S-methyltransferase, genotypic analysis
- Page(s) : 512-7
- DOI : 10.1684/ejd.2008.0473
- Année de parution : 2008
Thiopurine S-methyltransferase (TPMT) activity is inversely related to the risk of developing severe hematopoietic toxicity in patients treated with azathioprine. The aim of this study was to evaluate the usefulness of TPMT genotyping in severe cases of autoimmune bullous diseases treated with azathioprine. A retrospective study of TPMT genotyping was performed in patients with autoimmune bullous diseases hospitalized in a single centre between 1999 and 2006 and susceptible of being treated by azathioprine. Among 75 patients tested, 70 (93%) had a high TPMT activity and 5 (7%) an intermediate activity. TPMT genotyping was performed in 33/34 patients currently treated with azathioprine. Haematopoietic side-effects (usually moderate) were observed in 12/34 patients treated with a mean dosage of 2.7 mg/kg/day and occurred, despite a high predicted TPMT activity. No myelotoxicity was observed in the two patients with intermediate predicted TPMT activity (mean dosage: 1.7 mg/kg/day), who obtained a clinically complete remission. Although strongly recommended before azathioprine treatment, predicting TPMT activity appears only marginally helpful in patients with autoimmune bullous diseases, mainly for adjusting the azathioprine dosage. In addition, a normal TPMT genotyping is not a guarantee against the occurrence of haematological side-effects.